F-1/A: Innocan Pharma Targets Nasdaq with IPO for CBD Drug Development

Innocan Pharma Corporation is launching an initial public offering of units to list on Nasdaq, aiming to raise capital for its preclinical LPT-CBD drug development for chronic pain and expand its consumer wellness products.

Summary

• Innocan Pharma Corporation is a pharmaceutical tech company operating in two main segments: Pharmaceuticals and Consumer Wellness.
• The company is conducting an Initial Public Offering (IPO) of 1,538,462 units, each consisting of one common share and one warrant, with an estimated IPO price of $9.875 per unit (after a proposed 65-for-1 reverse share split).
• Proceeds from the IPO, estimated at $12.98 million net, will primarily fund research and development for human ($6.5 million) and veterinary ($2.5 million) applications of its LPT-CBD project, and $1 million for US marketing and sales.
• The LPT-CBD platform, a synthetic cannabidiol-loaded liposome injection, is in late pre-clinical development for chronic pain management and aims to provide prolonged, controlled release of CBD for up to four weeks.
• The company has initiated the FDA regulatory review process for LPT-CBD, including a successful pre-IND meeting, and plans to submit an Investigational New Drug (IND) application for Phase 1a human studies following scale-up activities.
• For veterinary applications, Innocan has received a sponsor fee waiver and an INAD number from the FDA-CVM, with an INAD application submission planned for the second half of 2025.
• The Consumer Wellness segment, including its 60%-owned joint venture B.I. Sky Global Ltd., develops and markets non-CBD personal care and beauty products online in the US, and CBD personal care products in Europe.
• Revenues increased significantly, from $13.657 million in 2023 to $29.437 million in 2024, and from $6.768 million in Q1 2024 to $7.796 million in Q1 2025, primarily driven by B.I. Sky's online sales.
• Net losses decreased from $(4.248) million in 2023 to $(262) thousand in 2024, and from $(1.454) million in Q1 2024 to $(229) thousand in Q1 2025.
• The company has an accumulated deficit of $35.490 million as of March 31, 2025, and its financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
• Innocan holds 31 published patents (granted and pending) across eight families, including one granted in India for liposomal cannabinoids and three granted for pain relief topical compositions.
• The global pain management market is projected to reach $109 billion by 2032, and the veterinary pain management market is expected to grow to $2.20 billion by 2029.
• The beauty and personal care market is projected to reach $693 billion by 2031, with the online segment growing to $161 billion by 2032.

Sentiment

Score: 6

Explanation: The filing presents a balanced view, highlighting significant growth in the consumer wellness segment and promising preclinical data for its pharmaceutical pipeline, alongside a clear strategy for IPO proceeds. However, it also explicitly details substantial risks associated with its preclinical stage, ongoing losses, reliance on future funding, and geopolitical instability in Israel, which temper overall positive sentiment.

Positives

• Significant revenue growth in the Consumer Wellness segment, with sales increasing from $13.657 million in 2023 to $29.437 million in 2024, and from $6.768 million in Q1 2024 to $7.796 million in Q1 2025.
• Net losses have substantially decreased, from $(4.248) million in 2023 to $(262) thousand in 2024, and from $(1.454) million in Q1 2024 to $(229) thousand in Q1 2025.
• Successful pre-IND meeting with the FDA for the LPT-CBD human application, structuring the development plan towards IND submission and acknowledging the 505(b)(2) abbreviated pathway.
• FDA's Center for Veterinary Medicine (CVM) granted a sponsor fee waiver and an INAD number for the LPT-CBD veterinary product, facilitating its development.
• Robust intellectual property portfolio with 31 published patents (granted and pending) across eight families, including a granted patent in India for liposomal cannabinoids.
• Preclinical studies for LPT-CBD have demonstrated promising results in animal models, showing sustained release of synthetic CBD, high bioavailability, and long-term analgesic effects with minimal side effects.
• The company's wellness products have strong market performance indicators, including over 5,100 units sold per day, a 0.01% return rate, and 87.4% customer return rate within 30 days.
• The IPO is expected to provide approximately $12.98 million in net proceeds, which management believes will fund operating expenses and capital expenditure requirements through January 2027.

Negatives

• The Pharmaceuticals segment is in the preclinical stage and has never generated revenue from LPT-CBD product sales, indicating a long and uncertain path to commercialization.
• The company has a history of net losses since its inception in 2018, with an accumulated deficit of $35.490 million as of March 31, 2025.
• The financial statements contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, highlighting significant financial risk.
• Future funding requirements are substantial, and there is no assurance that additional financing will be available on acceptable terms or at all, which could lead to curtailment or discontinuation of product development.
• The company is subject to intense competition and rapid technological change in both the pharmaceutical and wellness industries, with many competitors having significantly greater resources.
• Reliance on third parties for manufacturing and clinical trials introduces risks, including potential delays, unsatisfactory performance, and increased costs.
• The company's foreign private issuer status allows it to follow home country corporate governance practices, which may provide less protection to U.S. investors compared to U.S. domestic issuers.
• Operations in Israel expose the company to significant geopolitical risks, including armed conflicts and regional instability, which could disrupt supply chains, delay projects, and affect commercial relationships.

Risks

• We are a pre-clinical stage company and anticipate significant losses until we commercialize our pharmaceutical products.
• We may not achieve or maintain sufficient working capital to meet future obligations.
• We have never generated revenue from LPT CBD product sales in our Pharmaceuticals segment.
• We expect to need additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding may require us to curtail, delay, or discontinue operations.
• We have a history of net loss, and as of March 31, 2025, December 31, 2024 and December 31, 2023, we had an accumulated deficit of $35,490,000, $34,908,000 and $33,074,000, respectively. Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
• Our pharmaceutical product candidates are in preclinical development. We cannot assure that any product candidates will receive regulatory approval, necessary for commercialization.
• We may not receive, or may be delayed in receiving, necessary approvals for our CBD-loaded liposome platform (LPT-CBD) or future products, affecting our ability to grow.
• If the FDAs Section 505(b)(2) pathway for certain of our drug candidates is not available, the development of certain of our drug candidates will likely take significantly longer, cost significantly more and entail significantly greater complexity and risk than currently anticipated, and, in any case may not be successful.
• Legislative or regulatory reforms in the U.S. or EU may make it more difficult and costly to obtain regulatory clearances or approvals, or to manufacture, market, or distribute products after approval.
• Clinical and preclinical development is uncertain. Current pre-clinical programs may experience delays or may never advance to clinical trials, affecting our ability to obtain regulatory approvals or commercialize these programs.
• Future clinical trials may be delayed, certain programs may never advance, or may be more costly, affecting our ability to fund operations and impacting our business.
• Clinical trials may fail to show safety and effectiveness, preventing regulatory approval and commercialization.
• Even with completed preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain, potentially preventing approvals.
• Early-stage clinical trial results may not predict future results; initial data may not reflect final or later-stage trial outcomes.
• Research and development of central nervous system, or CNS, -targeting drugs is difficult, making it hard to predict why a drug works for some patients but not others.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development.
• Product candidates may have side effects or safety risks, delaying or halting development, preventing approval, or limiting commercial potential.
• Approved products may fail to achieve market acceptance, affecting revenue and profitability.
• Clinical trials conducted outside the U.S. may not be accepted by FDA, EMA, or other regulatory authorities.
• Failure to obtain regulatory approval in any jurisdiction could substantially harm our business.
• Complex pharmaceutical product candidates may face manufacturing problems, delaying development or commercialization.
• We may not use expedited development or regulatory review processes for breakthrough or fast track designated products.
• Approved products will face ongoing regulatory obligations and review, incurring additional expenses and potential penalties for non-compliance.
• If the market opportunities for our pharmaceutical product candidates are smaller than we believe, our revenue may be adversely affected. Our ability to identify patients and acquire a significant market share is necessary for profitability and growth.
• The commercial success of any future pharmaceutical products will depend on market acceptance by physicians, healthcare payers, patients, and the medical community.
• If we are unable to establish sales and marketing capabilities or enter agreements with third parties to sell and market any product candidates we develop, we may not successfully commercialize those product candidates.
• We face intense competition and rapid technological change, and our competitors may discover, develop, or commercialize therapies that are similar, more advanced, or more effective than ours.
• The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.
• Failure to comply with controlled substance legislation could restrict or harm our ability to develop and commercialize products.
• Cannabis remains illegal under U.S. federal law, and changes in enforcement priorities could render operations unprofitable or prohibit them.
• The cannabis industry and regulations continue to develop, and changes that differ from our expectations or are adverse to us may impact our business and operations.
• Failure to comply with various regulations could prevent us from carrying on our business and we may incur costs.
• We may become involved in disputes and legal or regulatory proceedings that, if adversely decided or settled, could materially affect our business, financial condition, and results of operations.
• We may be required to recall products and face product liability claims, resulting in unexpected costs and damaging our reputation.
• If our products are not manufactured in compliance with regulations, do not meet quality standards, or result in adverse health effects, it could cause reputational harm, remedial costs, or regulatory enforcement.
• New laws, regulations, enforcement trends, or changes in regulations governing the introduction, marketing, and sale of our products could harm our business.
• Our facilities and those of third-party manufacturers are subject to regulation under the FDCA and FDA regulations.
• Government regulations and private party actions relating to marketing may restrict, our ability to sell products and harm our business, financial condition, and results of operations.
• Government regulation of the Internet and e-commerce is evolving, and unfavorable changes or failure to comply could substantially harm our business, financial condition, and results of operations.
• Healthcare legislation aimed at reducing costs may have a material adverse effect on our business.
• Governments outside the United States may impose strict price controls, adversely affecting our revenues.
• We may seek additional collaborations and may not be successful in maintaining or entering new ones. Even if successful, we may not realize the benefits.
• We rely on third parties for clinical trials, research, and preclinical testing. These third parties may not perform satisfactorily.
• We have no sales, distribution, or marketing experience and may invest significant resources to establish these capabilities. Failure to do so or to enter agreements with third parties may prevent us from generating revenues.
• If we are unable to obtain and maintain effective intellectual property rights, we may not compete effectively.
• We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming, and unsuccessful.
• We need to expand our organization and may have difficulties managing growth, disrupting operations.
• We may not succeed in identifying, discovering, or licensing additional product candidates.
• Employment laws may prevent us from enforcing non-compete covenants, allowing competitors to benefit from former employees expertise.
• Our success depends on retaining executive officers and attracting, retaining, and motivating qualified personnel.
• Increasing scrutiny of sustainability and ESG initiatives could increase costs or impact our business.
• Unfavorable economic and market conditions and financial institution developments may adversely affect our business, operating results, and growth rates.
• We may be classified as a passive foreign investment company, causing adverse tax consequences for U.S. shareholders.
• As a foreign private issuer, we follow home country corporate governance practices and are not subject to certain U.S. securities laws and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation.
• As an emerging growth company, reduced disclosures may make us less attractive to investors.
• Recent initial public offerings (IPOs) of similar companies have experienced extreme volatility unrelated to performance. We may experience similar volatility, affecting the assessment of our shares value.
• Part of our operations are conducted in Israel. Conditions in Israel, including the recent conflict with Iran, attacks by Hamas and other terrorist organizations and Israels war against them, could materially and adversely affect our business.
• It may be difficult to enforce a U.S. judgment against us, our officers, and directors not in the U.S., or to assert U.S. securities laws claims or serve process on our officers and directors not in the U.S.
• We are governed by the corporate laws of Canada which in some cases have a different effect on shareholders than the corporate laws of the United States.
• Our business and operations might be adversely affected by security breaches, including cybersecurity incidents.
• Sales or significant short sales of our common shares, or the perception of such sales, could depress the market price and impair our ability to raise capital.
• If securities or industry analysts do not publish or cease publishing research or reports about us, or if they publish negative reports, our share price and trading volume could decline.

Future Outlook

The company intends to submit an IND application for its initial Phase 1a study for LPT-CBD human applications approximately one year after commencing scale-up activities, which are expected to begin three months following the IPO. A GLP-compliant single-injection preclinical safety study is anticipated to take 6-8 months, followed by the IND submission. Phase 1a first-in-human studies will commence 30 days post-IND submission, collecting pharmacokinetic and exposure data to form a scientific bridge to Epidiolex for a 505(b)(2) application, a process estimated to take 6-8 months in parallel. Phase 1b studies are planned to begin immediately after Phase 1a approval and completion of a repeated-dose GLP safety study. For animal health, an INAD application with the FDA-CVM is intended for the second half of 2025. The company expects existing capital resources combined with IPO proceeds to fund operations through January 2027. The Consumer Wellness segment plans to expand its product portfolio and reach across digital commerce, online channels, and distribution partners, with future plans to evolve to brick & mortar storefronts.

Management Comments

• We are committed to improving quality of life by addressing chronic pain in humans and animals through innovative therapeutic solutions.
• We believe that our diversified strategy across human pharmaceuticals, animal health, and wellness will help manage risk, support potential growth, and broaden market opportunities.
• We are committed to bringing safer, effective alternatives to the market, transforming the landscape of chronic pain management and wellness.
• We believe that progressing along a defined regulatory support and pathways will position us well in the market and on track to commercialization.

Industry Context

The filing highlights the urgent need for alternative pain management solutions due to the devastating opioid crisis, with opioids implicated in over 75% of U.S. drug overdose deaths and an estimated economic burden of nearly $1.5 trillion annually on the U.S. healthcare system. Innocan Pharma positions its LPT-CBD as a non-opioid alternative, aligning with the growing demand for safer pain relief methods. The global pain management market is projected to grow to $109 billion by 2032, driven by increasing chronic diseases and an aging population. The veterinary pain management market is also expanding, estimated at $1.65 billion in 2024 and expected to reach over $2.20 billion by 2029, fueled by increased pet ownership and awareness of pet health. The beauty and personal care market, projected to reach $693 billion by 2031, benefits from e-commerce expansion and rising demand for anti-aging and self-care products. Innocan's focus on sustained-release liposomal technology and compliance with regulations like MoCRA positions it within these growing markets, while facing intense competition from major pharmaceutical and beauty companies.

Comparison to Industry Standards

• The LPT-CBD platform aims to provide a non-opioid alternative for chronic pain management, addressing a critical need highlighted by the opioid crisis, which has strained healthcare systems and caused immense suffering.
• The company is pursuing the FDA's 505(b)(2) abbreviated pathway for LPT-CBD human health applications, leveraging existing data from Epidiolex (a CBD oral drug approved for epilepsy by GW Pharmaceuticals/Jazz Pharmaceuticals), which is a streamlined approach compared to a full NDA.
• Innocan's LPT-CBD demonstrated high bioavailability (approaching 100% in osteoarthritic dogs compared to 6.5%-20% for oral CBD) and prolonged release (up to four weeks from a single injection), offering a potential advantage over existing oral CBD formulations and traditional pain medications.
• The global pain management market is projected to grow at a CAGR of 4.5% to $109 billion by 2032, indicating a substantial market opportunity for new solutions like LPT-CBD.
• The veterinary pain management market is growing at a CAGR of 5.91% to $2.20 billion by 2029, driven by increased pet ownership and advanced care, where LPT-CBD for companion animals could compete with existing therapies.
• The beauty and personal care market is projected to grow at a CAGR of 4.35% to $693 billion by 2031, with the online segment growing at 11.5% to $161 billion by 2032, providing a large and expanding market for B.I. Sky's non-CBD products and Innocan's CBD products in Europe.
• The company faces intense competition from major pharmaceutical companies like Jazz Pharmaceuticals (owner of Epidiolex), AbbVie, Pfizer, Sanofi, and Bristol-Myers Squibb, which have significantly greater financial, technical, and human resources, and established market presence.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• Founders Agreement with Brandzon Co Ltd. (May 26, 2021) to establish B.I. Sky Global Ltd., with Innocan holding 60% and Brandzon 40%. Roni Kamhi, Innocan's COO, is CEO and co-founding director of B.I. Sky.
• Innocan extended an owner's loan of approximately $3,000,000 to B.I. Sky, bearing interest pursuant to Israeli Tax Ordinance Section 3(10). Repayment was extended until the earlier of February 15, 2026, or an exit event of B.I. Sky.
• Tamar Innovest Limited, a company associated with director Ralph C.L Bossino, participated in private placements in August 2023 (17,391 units for $179,400) and a secured convertible debenture offering in March 2025 ($1,000,000 gross proceeds).
• A loan of $14,291 was extended to CEO Iris Bincovich on July 1, 2020, and was fully repaid by December 31, 2023.

Stakeholder Impact

• Shareholders: Potential for dilution from the IPO and future capital raises, but also potential for increased share value if LPT-CBD development and commercialization are successful. Existing shareholders will experience immediate dilution of $5.62 per common share to new investors.
• Employees: Continued investment in R&D and expansion of operations may lead to increased hiring and career opportunities, but also risks associated with the company's going concern status and need for additional funding.
• Customers: Potential for new, innovative non-opioid pain management therapies for humans and animals, and continued expansion of self-care and beauty product offerings.
• Suppliers: Continued reliance on third-party manufacturers and service providers for product development and manufacturing, potentially leading to increased business for these partners.
• Creditors: The company's accumulated deficit and going concern opinion raise risks for creditors, though the IPO aims to improve liquidity and financial stability.

Next Steps

• Complete LPT-CBD scale-up activities for human applications (expected to commence ~3 months after IPO and take ~1 year).
• Conduct a Good Laboratory Practice (GLP)-compliant single-injection preclinical safety study for LPT-CBD (anticipated within 6-8 months).
• Submit an Investigational New Drug (IND) application to the FDA for the initial Phase 1a study for human LPT-CBD, including clinical protocol and safety report.
• Commence Phase 1a first-in-human study 30 days post-IND submission (assuming no clinical hold).
• Collect pharmacokinetic (PK) and exposure data of LPT-CBD during Phase 1a studies to form a scientific bridge to Epidiolex for a 505(b)(2) application (estimated 6-8 months, parallel to Phase 1a).
• Begin Phase 1b studies immediately following approval of Phase 1a study results and completion of a repeated-dose GLP safety study.
• Submit an INAD application with the FDA-CVM for veterinary LPT-CBD during the second half of 2025.
• Perform an efficacy pilot, full Chemistry, Manufacturing, and Controls (CMC) development, and scale-up for veterinary LPT-CBD.
• Engage pharmaceutical companies and industry leaders in licensing discussions for human and animal health applications once key regulatory milestones are achieved for LPT-CBD.
• Continue to expand the product portfolio and invest in product reach across digital commerce, online channels, and distribution partners for the Consumer Wellness segment.
• Maintain compliance with US rules regarding personal care and beauty products, including MoCRA.

Key Dates

Keywords

Pharmaceuticals, CBD, Liposome Technology, Chronic Pain Management, IPO, Nasdaq, Biotechnology, Consumer Wellness, Drug Delivery, Preclinical Development, FDA Approval, Cannabinoids, Israel, Medical Devices, E-commerce